-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 DgxBwqVHXj+PHOcht7j2wpxuFVYHeonfw3QGAdFrzpoa2KMJkRqAa0f3jRub2Oge
 oeOBy3W9ZBe4psd39KJWpw==

<SEC-DOCUMENT>0001013762-05-000539.txt : 20050510
<SEC-HEADER>0001013762-05-000539.hdr.sgml : 20050510
<ACCEPTANCE-DATETIME>20050510101138
ACCESSION NUMBER:		0001013762-05-000539
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20050510
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20050510
DATE AS OF CHANGE:		20050510

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			APPLIED DNA SCIENCES INC
		CENTRAL INDEX KEY:			0000744452
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				592262718
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	002-90539
		FILM NUMBER:		05814239

	BUSINESS ADDRESS:	
		STREET 1:		9229 WEST SUNSET BOULEVARD, SUITE 830
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90069
		BUSINESS PHONE:		3108601362

	MAIL ADDRESS:	
		STREET 1:		9229 WEST SUNSET BLVD, SUITE 830
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90069

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PROHEALTH MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	20010504

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DCC ACQUISITION CORP
		DATE OF NAME CHANGE:	19990211

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DATALINK CAPITAL CORP/TX/
		DATE OF NAME CHANGE:	19980306
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>may1020058k.txt
<TEXT>
                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

        Date of Report (Date of earliest event reported): March 24, 2005

                           Applied DNA Sciences, Inc.
             (Exact name of registrant as specified in its charter)



          Nevada                       002-90539               59-2262718
- --------------------------------------------------------------------------------
(State or other jurisdiction     (Commission File Number)      (IRS Employer
     of incorporation)                                       Identification No.)


             9229 Sunset Boulevard, Suite 83, Los Angeles, CA 90069
              (Address of principal executive offices and Zip Code)

        Registrant's telephone number, including area code (310) 860-1362

                                   Copies to:
                              Andrea Cataneo, Esq.
                       Sichenzia Ross Friedman Ference LLP
                           1065 Avenue of the Americas
                            New York, New York 10018
                              Phone: (212) 930-9700
                               Fax: (212) 930-9725

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ] Soliciting  material  pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))





<PAGE>

Item 1.01 Entry into a Material Definitive Agreement.

     On March 24, 2005, Applied DNA Sciences,  Inc. (the "Company") entered into
an amendment  (the  "Amendment")  to the  Cooperative  Research and  Development
Agreement  ("CRADA")  with  Battelle  Energy  Alliance,  LLC, the  Department of
Energy's  National   Laboratory  in  Idaho  Falls,  Idaho.  The  Amendment  adds
additional joint research projects, including development of marker applications
for textiles, inks, gasoline, and explosive materials.

Item 9.01 Financial Statements and Exhibits.

(a)      Financial statements of business acquired.

         Not applicable.

(b)      Pro forma financial information.

         Not applicable.

(c)      Exhibits.

Exhibit Number                       Description
- -------------- -----------------------------------------------------------------
10.1                Amendment  to  the  Cooperative   Research  and  Development
                    Agreement,  dated  as of  March  24,  2005,  by and  between
                    Applied DNA  Sciences,  Inc. and Battelle  Energy  Alliance,
                    LLC.

<PAGE>
                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                              Applied DNA Sciences, Inc.


Date: May 10, 2005                            /s/ ROB HUTCHISON
                                              -----------------
                                              Rob Hutchison
                                              Chief Executive Officer




</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>2
<FILENAME>may1020058kex101.txt
<TEXT>
Exhibit 10.1

                                MODIFICATION NO.1

                                       TO

             STEVENSON-WYDLER (15 USC 3710) COOPERATIVE RESEARCH AND
            DEVELOPMENT AGREEMENT (hereinafter "CRADA") No. 04-CR-09

                                     BETWEEN

   Battelle Energy Alliance, LLC under its U.S. Department of Energy Contract
                No. ED-AC07-05ID14517 (hereinafter "Contractor")

                                       AND

             Applied DNA Sciences, Inc. (hereinafter "Participant"),

     hereinafter referred to singularly as "Party" and jointly as "Parties"

Whereas both Parties  desire to modify CRADA No.  04-CR-09;  the Parties  hereby
agree to incorporate the following changes:

1.   Replace  Article III,  Paragraph A with "The  effective  date of this CRADA
     shall be the latter  date of (1) the date on which it is signed by the last
     of the  Parties,  (2) the date on which it is  approved  by DOE, or (3) the
     date on which the advance funding  referred to in Article III.B is received
     by the  Contractor.  The work to be  performed  under this  CRADA  shall be
     complete within three (3) years from the effective date.

2.   Replace Article III, Paragraph B with "Participant's estimated contribution
     is $50,000 funds-in and $0 in-kind for FT-04 and $1,701,216 funds-in and $0
     in-kind for FY-05.  There is no  Government  funding  associated  with this
     CRADA.

3.   Replace the Contractor information under Article XXVII: NOTICES as follows:

     Agreements Administrator
     Technology Transfer & Commercialization
     Battelle Energy Alliance, LLC
     2525 N. Fremont Ave.
     P.O. Box 1625, MS 3805
     Idaho Falls, ID 83415-3805
     E-mail: agradmin@inl.gov
     Phone: (208) 526-6141
     Fax: (208) 526-0876


<PAGE>
4.   Add the following  paragraph to Appendix A, "Statement of Work",  paragraph
     10 "Further develop and refine the selected applications:

     Validate  Biowell  Embedded  DNA  Technology,  including:  1) marker  DNA &
     primer/probe  characterization,  2) unique DNA  productions  and  embedding
     methods  assessment,   validation  replication,  and  enhancement,  and  3)
     embedding  matrix  material  analysis,   signature  signal  assessment  and
     stand-off detection methods. In addition, develop a new product application
     including:   1)  thread  detection  methods   validation,   RT-PCR  methods
     development  and  protocol   standardization;   2)  ink  detection  methods
     validation,   RT-PCR  methods  development  and  protocol  standardization;
     gasoline  methods  validation,  RT-PCR  methods  development  and  protocol
     standardization;  and 4) explosive  materials detection methods validation,
     RT-PCR methods development and protocol standardization. Also develop a new
     petroleum product application including stand-off sensing.

5.   Delete the header "Timeline:" and associated table in the scope of work.

ACCEPTED TO AND AGREED TO:

FOR BATTELLE ENERGY ALLIANCE, LLC

BY:               /s/ A. RAY BARNES
                  -----------------
PRINTED NAME:     A. RAY BARNES

TITLE:            Group Manager, Technology Transfer & Commercialization

DATE:             March 24, 2005


FOR APPLIED DNA SCIENCES, INC.

BY:               /s/ KARIN KLEMM
                  ---------------
PRINTED NAME:     Karim Klemm

TITLE:            Chief Operating Officer/Chief Financial Officer

DATE:             March 24, 2005


</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
